Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) Gross Margin (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Gross Margin for 15 consecutive years, with 77.15% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin fell 324.0% to 77.15% in Q3 2025 year-over-year; TTM through Sep 2025 was 79.18%, a 168.0% decrease, with the full-year FY2024 number at 81.13%, up 32.0% from a year prior.
  • Gross Margin was 77.15% for Q3 2025 at Usana Health Sciences, down from 78.72% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 81.95% in Q4 2024 to a low of 1748893.75% in Q3 2021.
  • A 5-year average of 122691.83% and a median of 80.86% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -174897534bps in 2021, then surged 174897503bps in 2022.
  • Usana Health Sciences' Gross Margin stood at 81.51% in 2021, then plummeted by -73bps to 22.34% in 2022, then surged by 262bps to 80.86% in 2023, then increased by 1bps to 81.95% in 2024, then dropped by -6bps to 77.15% in 2025.
  • Per Business Quant, the three most recent readings for USNA's Gross Margin are 77.15% (Q3 2025), 78.72% (Q2 2025), and 78.98% (Q1 2025).